ASCO GU 2023 Bladder Cancer - Results from #40

Viewing 41-54 of 54 articles

ASCO GU 2023: Chemotherapy, Immunotherapy, or Combination First-Line Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Large Real-World Experience

ASCO GU 2023: SunRISe-4: TAR-200 plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer (MIBC) Who Are Ineligible for or Refuse Neoadjuvant Platinum-Based Chemotherapy

ASCO GU 2023: Phase 2 KEYNOTE-057 Cohort C: Pembrolizumab with Vibostolimab or Favezelimab for Patients with High-Risk Bacillus Calmette-Guérin (BCG)-Unresponsive Non–muscle-Invasive Bladder Cancer (NMIBC)

ASCO GU 2023: Phase 3 KEYNOTE-905/EV-303: Perioperative Pembrolizumab (Pembro) or Pembro + Enfortumab Vedotin for Muscle-Invasive Bladder Cancer (MIBC)

ASCO GU 2023: Racial and Geographical Disparities in Pivotal Bladder Cancer Clinical Trials

ASCO GU 2023: A Phase 1, Open-Label Trial to Evaluate Feasibility and Safety of Intramural Injection of Belzupacap Sarotalocan (AU-011) in Non-Muscle–invasive Bladder Cancer (NMIBC)

ASCO GU 2023: Benefit of Whole-Pelvis Radiation for Patients with Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment-Weighted Analysis

ASCO GU 2023: Phase Ib/II Study of Neoadjuvant Pembrolizumab and Chemotherapy for T2-4aN0M0 Urothelial Cancer (HCRN GU14-188)

ASCO GU 2023: Co-Primary Endpoint Analysis of HCRN GU 16-257: Phase 2 Trial of Gemcitabine, Cisplatin, plus Nivolumab with Selective Bladder Sparing in Patients with Muscle-Invasive Bladder Cancer (MIBC)

ASCO GU 2023: Cell-Free Urinary Tumor DNA to Detect Minimal Residual Disease Prior to Repeat-Transurethral Resection of Bladder Tumor in Non–muscle-Invasive Bladder Cancer: A Prospective Study

ASCO GU 2023: Intravesical Gemcitabine and Docetaxel in the Treatment of BCG-Naïve Non–muscle Invasive Urothelial Carcinoma of the Bladder: Updates from a Phase 2 Trial

ASCO GU 2023: Quality of Life in QUILT 3.032 Study: Patients with BCG-Unresponsive NMIBC Receiving IL-15RαFc Superagonist N-803 plus BCG

ASCO GU 2023: A Phase 2 Basket Study of Tucatinib and Trastuzumab in Previously Treated Solid Tumors with HER2 Alterations: Urothelial Cancer Cohort (SGNTUC-019)

ASCO GU 2023: Complimentary Genomic, Pathologic, and Artificial Intelligence Analysis on Low-Grade Noninvasive Bladder Cancer to Predict Downstream Recurrence

1
2
3